Skip to main content

Table 2 The effects of every single lipoprotein apheresis therapy during the monitored interval of 15 years on selected parameters of lipid metabolism, inflammatory biomarkers, and soluble endoglin

From: Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

Parameter HeFH (n = 10) HoFH (n = 4)
Lipids, mmol/l Before LA After LA Decrease, n (%) patients Before LA After LA Decrease, n (%) patients
TC 5.69 (1.16) 1.93 (0.59)*** 10 (100) 7.09 (2.15) 1.95 (0.66)*** 4 (100)
LDLC 3.57 (1.19) 0.75 (0.54)*** 10 (100) 5.13 (1.87) 0.85 (0.94)*** 4 (100)
HDLC 1.34 (0.65) 0.91 (0.33)*** 10 (100) 1.51 (0.72) 1.15 (0.39)*** 4 (100)
ApoB 1.11 (0.28) 0.28 (0.22)*** 10 (100) 1.22 (0.50) 0.18 (0.17)*** 4 (100)
Endoglin, ng/mL 6.45 (1.85) 5.56 (1.75)*** 8 (80) 6.22 (1.73) 4.85 (1.80)*** 3 (75)
CD40L, pg/mL 5323 (2059) 5367 (3093) 4 (40) 5177 (1585) 4239 (1892) 2 (50)
hsCRP, mg/L 2.84 (1.51) 2.39 (1.38) 6 (60) 2.21 (1.36) 1.82 (1.27) 3 (75)
MCP-1, pg/mL 321.8 (99.2) 274.5 (86.1) 6 (60) 265.6 (71.0) 221.4 (68.2) 3 (75)
sP-selectin, ng/mL 148.1 (50.7) 131.7 (53.8)* 7 (70) 145.6 (70.6) 154.3 (212.2) 3 (75)
  1. Data shows the level of parameters before and after each procedure during the time patients underwent LA and the percentage of cases (patients) where change was significant
  2. *p < 0.05, ***p < 0.001